<DOC>
	<DOCNO>NCT01179659</DOCNO>
	<brief_summary>The objective study ass single-dose bioequivalence KUDCO 's Wyeth Pharmaceuticals ' ( Protonix ) 40 mg pantoprazole sodium delayed-lease tablet , fed condition .</brief_summary>
	<brief_title>Bioequivalence Study Pantoprazole 40 mg DR Tablets Protonix 40 mg Tablets Under Fed Conditions</brief_title>
	<detailed_description>This open-label , randomize , fully replicate crossover , 2-sequence bioequivalence study feed condition .</detailed_description>
	<mesh_term>Pantoprazole</mesh_term>
	<criteria>Healthy , adult , nonsmoking ( least 6 month ) male female volunteer , 18 55 year age . Weighed least 52 kg male 45 kg female within 15 % ideal weight ( Table `` Desirable Weights Adults '' , Metropolitan Life Insurance Company , 1983 ) . Medically healthy subject clinically normal laboratory profile , vital sign , ECG . Females childbearing potential either sexually inactive ( abstinent ) 14 day prior first dose throughout study , use one follow acceptable birth control method : 1 . Surgically sterile ( bilateral tubal ligation , hysterectomy , bilateral oophorectomy ) 6 month minimum . 2 . Intrauterine device ( IUD ) place least 3 month . 3 . Barrier method ( condom , diaphragm ) spermicide least 14 day prior first dose throughout study . 4 . Surgical sterilization partner ( vasectomy 6 month minimum ) . 5 . Hormonal contraceptive least 3 month prior first dose study . Gave voluntary write informed consent participate study . History presence significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease . In addition , history presence : 1 . Alcoholism drug abuse within past 2 year ; 2 . Hypersensitivity idiosyncratic reaction pantoprazole , omeprazole , substitute benzimidazole protonpump . inhibitor . Females pregnant lactating . History tobacco use use product contain nicotine ( i.e. , smoke cessation aid nicotine gum patch ) within 6 month prior first dose . Subjects test positive screening human immunodeficiency virus ( HIV ) antibody screen , hepatitis B surface antigen screen ( HbsAg ) , hepatitis C antibody screen ( HCV ) . Treatment known enzymealtering drug ( barbiturate , phenothiazine , cimetidine , etc . ) within 30 day prior first dose . Difficulty swallow medication gastrointestinal disease would affect drug absorption . Subjects special diet ( whatever reason ) 28 day prior first dose throughout study . Subjects , completion study , would donate excess : 500 mL blood 14 day ; 1500 mL blood 180 day ; 2500 mL blood one year . Subjects participate another clinical trial 28 day prior first dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Single dose crossover BE study</keyword>
</DOC>